DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
-10.55%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$353M
AUM Growth
+$353M
(-10%)
Cap. Flow
+$9.89M
Cap. Flow
% of AUM
2.8%
Top 10 Holdings %
Top 10 Hldgs %
52.84%
Holding
90
New
8
Increased
24
Reduced
15
Closed
7
Top Buys
| 1 |
Arcus Biosciences
RCUS
|
$2.91M |
| 2 |
Mineralys Therapeutics
MLYS
|
$2.58M |
| 3 |
Stoke Therapeutics
STOK
|
$1.81M |
| 4 |
Inogen
INGN
|
$1.78M |
| 5 |
Denali Therapeutics
DNLI
|
$1.74M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$3.58M |
| 2 |
Axogen
AXGN
|
$3.07M |
| 3 |
AtriCure
ATRC
|
$1.59M |
| 4 |
Alkermes
ALKS
|
$875K |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
$816K |
Sector Composition
| 1 | Healthcare | 85.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Sutro Biopharma
STRO
$85.6M
| $284K | 0.08% |
437,079
| – | – |
|
77
Aprea Therapeutics
APRE
$8.91M
| $280K | 0.08% |
137,174
| – | – |
|
78
BiomX
PHGE
$14.1M
| $223K | 0.06% |
401,136
| – | – |
|
|
NVRO
79
DELISTED
NEVRO CORP.
NVRO
| $222K | 0.06% |
38,000
| – | – |
|
80
Black Diamond Therapeutics
BDTX
$164M
| $217K | 0.06% |
140,000
| – | – |
|
81
Spero Therapeutics
SPRO
$117M
| $90K | 0.03% |
125,000
| – | – |
|
82
Tenaya Therapeutics
TNYA
$192M
| $27K | 0.01% |
+47,319
| New | +$27K |
|
83
Vir Biotechnology
VIR
$765M
| – | – |
-100,000
| Closed | -$734K |
|
|
SLRN
84
DELISTED
ACELYRIN
SLRN
| – | – |
-87,989
| Closed | -$276K |
|
|
CNTA
85
Centessa Pharmaceuticals
CNTA
$2.13B
| – | – |
-47,453
| Closed | -$795K |
|
86
Compass Therapeutics
CMPX
$466M
| – | – |
-158,394
| Closed | -$230K |
|
87
Perspective Therapeutics
CATX
$251M
| – | – |
-130,169
| Closed | -$415K |
|
88
Acrivon Therapeutics
ACRV
$42.2M
| – | – |
-112,414
| Closed | -$677K |
|
89
Masimo
MASI
$7.43B
| – | – |
-3,000
| Closed | -$496K |
|